DEVELOPMENT AND CHARACTERIZATION OF DIBUCAINE-LOADED SOLID LIPID NANOPARTICLES BY HIGH-PRESSURE HOMOGENIZATION FOR ENHANCED LOCAL ANESTHETIC EFFICACY AND SAFETY

Dibucaine (DBC), a highly potent amide-type local anesthetic, is limited in clinical use by poor aqueous solubility, rapid systemic absorption, and narrow therapeutic index, which increase risks of CNS and cardiovascular toxicity. This study aimed to develop and comprehensively characterize DBC-loaded solid lipid nanoparticles (SLNs) using high-pressure homogenization to achieve sustained release, enhanced local efficacy, and improved safety profile. SLNs were prepared with myristyl myristate (SLNM) or cetyl palmitate (SLNCP) as lipid matrices (5% w/v), stabilized by Pluronic F68 (1% w/v), and loaded with 0.5% w/v DBC. The formulations exhibited high encapsulation efficiency (92.4 ± 2.1% for SLNM; 89.7 ± 1.8% for SLNCP), nanoscale hydrodynamic diameters (148.7 ± 3.9 nm and 162.4 ± 4.1 nm, respectively), low polydispersity indices (<0.25), and strongly negative zeta potentials (–29.6 to –32.1 mV), remaining stable over 240 days at 4°C. Transmission electron microscopy confirmed spherical morphology with distinct core-shell architecture. Differential scanning calorimetry revealed reduced crystallinity (74–77%), while electron paramagnetic resonance demonstrated increased lipid fluidity upon DBC incorporation. In vitro release studies showed biphasic, sustained Fickian diffusion profiles (Weibull β < 0.75; Korsmeyer-Peppas n < 0.44), with 72.4% and 68.7% cumulative release at 48 h from SLNM and SLNCP, respectively, compared to rapid release of free DBC. MTT assays on BALB/c 3T3 fibroblasts and HaCaT keratinocytes indicated significantly reduced cytotoxicity (>85% viability at 2.1 mmol/L vs. <60% for free DBC). In vivo tail-flick tests in Wistar rats demonstrated prolonged antinociception, with recovery time extended by 142% (SLNM) and 128% (SLNCP) compared to free DBC (p < 0.01). These results establish DBC-loaded SLNs as a promising, biocompatible nanoplatform for safer, longer-acting local anesthesia, with potential applications in infiltrative and postoperative pain management.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-12-23
DOI
https://doi.org/10.5281/zenodo.18465106
Primary Topic
Advancements in Transdermal Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

DEVELOPMENT AND CHARACTERIZATION OF DIBUCAINE-LOADED SOLID LIPID NANOPARTICLES BY HIGH-PRESSURE HOMOGENIZATION FOR ENHANCED LOCAL ANESTHETIC EFFICACY AND SAFETY

Pankaj Gill1, Dr. Umesh Kumar*2, Manju Rani3, Km Ankush4
Zenodo (CERN European Organization for Nuclear Research)
Advancements in Transdermal Drug Delivery
article

DEVELOPMENT AND CHARACTERIZATION OF DIBUCAINE-LOADED SOLID LIPID NANOPARTICLES BY HIGH-PRESSURE HOMOGENIZATION FOR ENHANCED LOCAL ANESTHETIC EFFICACY AND SAFETY

Pankaj Gill1, Dr. Umesh Kumar*2, Manju Rani3, Km Ankush4
article en

Abstract

Dibucaine (DBC), a highly potent amide-type local anesthetic, is limited in clinical use by poor aqueous solubility, rapid systemic absorption, and narrow therapeutic index, which increase risks of CNS and cardiovascular toxicity. This study aimed to develop and comprehensively characterize DBC-loaded solid lipid nanoparticles (SLNs) using high-pressure homogenization to achieve sustained release, enhanced local efficacy, and improved safety profile. SLNs were prepared with myristyl myristate (SLNM) or cetyl palmitate (SLNCP) as lipid matrices (5% w/v), stabilized by Pluronic F68 (1% w/v), and loaded with 0.5% w/v DBC. The formulations exhibited high encapsulation efficiency (92.4 ± 2.1% for SLNM; 89.7 ± 1.8% for SLNCP), nanoscale hydrodynamic diameters (148.7 ± 3.9 nm and 162.4 ± 4.1 nm, respectively), low polydispersity indices (<0.25), and strongly negative zeta potentials (–29.6 to –32.1 mV), remaining stable over 240 days at 4°C. Transmission electron microscopy confirmed spherical morphology with distinct core-shell architecture. Differential scanning calorimetry revealed reduced crystallinity (74–77%), while electron paramagnetic resonance demonstrated increased lipid fluidity upon DBC incorporation. In vitro release studies showed biphasic, sustained Fickian diffusion profiles (Weibull β < 0.75; Korsmeyer-Peppas n < 0.44), with 72.4% and 68.7% cumulative release at 48 h from SLNM and SLNCP, respectively, compared to rapid release of free DBC. MTT assays on BALB/c 3T3 fibroblasts and HaCaT keratinocytes indicated significantly reduced cytotoxicity (>85% viability at 2.1 mmol/L vs. <60% for free DBC). In vivo tail-flick tests in Wistar rats demonstrated prolonged antinociception, with recovery time extended by 142% (SLNM) and 128% (SLNCP) compared to free DBC (p < 0.01). These results establish DBC-loaded SLNs as a promising, biocompatible nanoplatform for safer, longer-acting local anesthesia, with potential applications in infiltrative and postoperative pain management.

Zenodo (CERN European Organization for Nuclear Research)
Openalex Percentile: Top 33%
Advancements in Transdermal Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.